--HC Wainwright Adjusts BioXcel Therapeutics' Price Target to $110 from $134, Keeps Buy Rating
10:47AM ET 5/23/2022 MT NewswiresPrice: 13.14, Change: -0.43, Percent Change: -3.21 ...
--UBS Adjusts BioXcel Therapeutics Price Target to $18 From $27, Maintains Buy Rating
12:04PM ET 5/12/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
--Berenberg Bank Adjusts BioXcel Therapeutics Price Target to $69 From $73, Maintains Buy Rating
8:05AM ET 5/11/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
-- Earnings Flash (BTAI) BIOXCEL THERAPEUTICS Posts Q1 Loss $-1.12, vs. Street Est of $-1.09
7:03AM ET 5/09/2022 MT Newswires...
BioXcel Therapeutics Launches Oncology Unit, Signs $260 Million in Financing Deals for Igalmi; Shares Rise Pre-Bell
7:40AM ET 4/19/2022 MT NewswiresBioXcel Therapeutics (BTAI) said Tuesday that it has created a wholly owned subsidiary called OnkosXcel Therapeutics, Inc. to develop transformative...
--HC Wainwright Adjusts Price Target on BioXcel Therapeutics to $134 From $130, Maintains Buy Rating
6:24AM ET 4/14/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
UBS Adjusts BioXcel Therapeutics Price Target to $27 From $25, Maintains Buy Rating
11:30AM ET 4/07/2022 MT NewswiresBioXcel Therapeutics (BTAI) has an average rating of Buy and price targets ranging from $17 to $130, according to analysts polled by Capital IQ. (MT...
Sector Update: Health Care Stocks Finish Higher on Wednesday
4:10PM ET 4/06/2022 MT NewswiresHealth care stocks continued to add their Wednesday advance, with the NYSE Health Care Index and the SPDR Health Care Select Sector ETF (XLV) rising 1.9%...
Sector Update: Health Care Stocks Climbing Wednesday Afternoon
2:07PM ET 4/06/2022 MT NewswiresHealth care stocks were mostly higher this afternoon, with the NYSE Health Care Index and the SPDR Health Care Select Sector ETF (XLV) both rising 1.0%. ...
BofA Securities Adjusts BioXcel Therapeutics Price Target to $80 From $78, Maintains Buy Rating
11:33AM ET 4/06/2022 MT NewswiresBioXcel Therapeutics (BTAI) has an average rating of Buy and price targets ranging from $16 to $130, according to analysts polled by Capital IQ. (MT...